|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Dicker D, Pain A, Hamavid H,
Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et
al: The global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Waddell T, Chau I, Cunningham D, Gonzalez
D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G,
Wadsley J, et al: Epirubicin, oxaliplatin, and capecitabine with or
without panitumumab for patients with previously untreated advanced
oesophagogastric cancer (REAL3): A randomised, open-label phase 3
trial. Lancet Oncol. 14:481–489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hingorani M, Crosby T, Maraveyas A, Dixit
S, Bateman A and Roy R: Neoadjuvant chemoradiotherapy for
resectable oesophageal and gastro-oesophageal junction cancer-do we
need another randomised trial. Clin Oncol (R Coll Radiol).
23:696–705. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Benetatos L, Vartholomatos G and
Hatzimichael E: Polycomb group proteins and MYC: The cancer
connection. Cell Mol Life Sci. 71:257–269. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferretti R, Bhutkar A, McNamara MC and
Lees JA: BMI1 induces an invasive signature in melanoma that
promotes metastasis and chemoresistance. Genes Dev. 30:18–33. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jin X, Kim LJY, Wu Q, Wallace LC, Prager
BC, Sanvoranart T, Gimple RC, Wang X, Mack SC, Miller TE, et al:
Targeting glioma stem cells through combined BMI1 and EZH2
inhibition. Nat Med. 23:1352–1361. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ren H, Du P, Ge Z, Jin Y, Ding D, Liu X
and Zou Q: TWIST1 and BMI1 in cancer metastasis and
chemoresistance. J Cancer. 7:1074–1080. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen D, Wu M, Li Y, Chang I, Yuan Q,
Ekimyan-Salvo M, Deng P, Yu B, Yu Y, Dong J, et al: Targeting
BMI1(+) cancer stem cells overcomes chemoresistance and inhibits
metastases in squamous cell carcinoma. Cell Stem Cell. 20:621–634.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kreso A, van Galen P, Pedley NM,
Lima-Fernandes E, Frelin C, Davis T, Cao L, Baiazitov R, Du W,
Sydorenko N, et al: Self-renewal as a therapeutic target in human
colorectal cancer. Nat Med. 20:29–36. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Q, Li Z, Wu Y, Huang R, Zhu Y, Zhang
W, Wang Y and Cheng J: Pharmacological inhibition of Bmi1 by
PTC-209 impaired tumor growth in head neck squamous cell carcinoma.
Cancer Cell Int. 17:1072017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cancer Genome Atlas Research N, Analysis
Working Group, ; Asan U, Agency BCC, et al: Integrated genomic
characterization of oesophageal carcinoma. Nature. 541:169–175.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jo S, Lee YL, Kim S, Lee H and Chung H:
PCGF2 negatively regulates arsenic trioxide-induced PML-RARA
protein degradation via UBE2I inhibition in NB4 cells. Biochim
Biophys Acta. 1863:1499–1509. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang CY, Kuo CH, Pai PY, Ho TJ, Lin YM,
Chen RJ, Tsai FJ, Vijaya Padma V, Kuo WW and Huang CY: Inhibition
of HSF2 SUMOylation via MEL18 upregulates IGF-IIR and leads to
hypertension-induced cardiac hypertrophy. Int J Cardiol.
257:283–290. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu X, Wei W, Li X, Shen P, Ju D, Wang Z,
Zhang R, Yang F, Chen C, Cao K, et al: BMI1 and MEL18 promote
colitis-associated cancer in Mice via REG3B and STAT3.
Gastroenterology. 153:1607–1620. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Won HY, Lee JY, Shin DH, Park JH, Nam JS,
Kim HC and Kong G: Loss of Mel-18 enhances breast cancer stem cell
activity and tumorigenicity through activating notch signaling
mediated by the Wnt/TCF pathway. FASEB J. 26:5002–5013. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jo S, Lee H, Kim S, Hwang EM, Park JY,
Kang SS and Chung H: Inhibition of PCGF2 enhances granulocytic
differentiation of acute promyelocytic leukemia cell line HL-60 via
induction of HOXA7. Biochem Biophys Res Commun. 416:86–91. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ji H, Cao M, Ren K, Sun N, Wang W, Zhu Q,
Zang Q and Jiang Z: Expression and clinicopathological significance
of Mel-18 and Bmi-1 in esophageal squamous cell carcinoma. Technol
Cancer Res Treat. 1533034617705055. 2017. View Article : Google Scholar
|
|
19
|
Guo BH, Zhang X, Zhang HZ, Lin HL, Feng Y,
Shao JY, Huang WL, Kung HF and Zeng MS: Low expression of Mel-18
predicts poor prognosis in patients with breast cancer. Ann Oncol.
21:2361–2369. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu YW, Li J and Guo WJ: Expression and
clinicopathological significance of Mel-18 and Bmi-1 mRNA in
gastric carcinoma. J Exp Clin Cancer Res. 29:1432010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang W, Lin T, Huang J, Hu W, Xu K and Liu
J: Analysis of Mel-18 expression in prostate cancer tissues and
correlation with clinicopathologic features. Urol Oncol.
29:244–251. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tao J, Liu YL, Zhang G, Ma YY, Cui BB and
Yang YM: Expression and clinicopathological significance of Mel-18
mRNA in colorectal cancer. Tumour Biol. 35:9619–9625. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dukers DF, van Galen JC, Giroth C, Jansen
P, Sewalt RG, Otte AP, Kluin-Nelemans HC, Meijer CJ and Raaphorst
FM: Unique polycomb gene expression pattern in Hodgkin's lymphoma
and Hodgkin's lymphoma-derived cell lines. Am J Pathol.
164:873–881. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zakrzewska M, Zakrzewski K, Gresner SM,
Piaskowski S, Zalewska-Szewczyk B and Liberski PP: Polycomb genes
expression as a predictor of poor clinical outcome in children with
medulloblastoma. Child's Nerv Syst. 27:79–86. 2011. View Article : Google Scholar
|
|
25
|
Vekony H, Raaphorst FM, Otte AP, van
Lohuizen M, Leemans CR, van der Waal I and Bloemena E: High
expression of Polycomb group protein EZH2 predicts poor survival in
salivary gland adenoid cystic carcinoma. J Clin Pathol. 61:744–749.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vekony H, Roser K, Loning T, Raaphorst FM,
Leemans CR, Van der Waal I and Bloemena E: Deregulated expression
of p16INK4a and p53 pathway members in benign and malignant
myoepithelial tumours of the salivary glands. Histopathology.
53:658–666. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jung JH, Choi HJ, Maeng YS, Choi JY, Kim
M, Kwon JY, Park YW, Kim YM, Hwang D and Kwon YG: Mel-18, a
mammalian polycomb gene, regulates angiogenic gene expression of
endothelial cells. Biochem Biophys Res Commun. 400:523–530. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park JH, Lee JY, Shin DH, Jang KS, Kim HJ
and Kong G: Loss of Mel-18 induces tumor angiogenesis through
enhancing the activity and expression of HIF-1alpha mediated by the
PTEN/PI3K/Akt pathway. Oncogene. 30:4578–4589. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guo WJ, Datta S, Band V and Dimri GP:
Mel-18, a polycomb group protein, regulates cell proliferation and
senescence via transcriptional repression of Bmi-1 and c-Myc
oncoproteins. Mol Biol Cell. 18:536–546. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo WJ, Zeng MS, Yadav A, Song LB, Guo BH,
Band V and Dimri GP: Mel-18 acts as a tumor suppressor by
repressing Bmi-1 expression and down-regulating Akt activity in
breast cancer cells. Cancer Res. 67:5083–5089. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang XW, Sheng YP, Li Q, Qin W, Lu YW,
Cheng YF, Liu BY, Zhang FC, Li J, Dimri GP and Guo WJ: BMI1 and
Mel-18 oppositely regulate carcinogenesis and progression of
gastric cancer. Mol Cancer. 9:402010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Akasaka T, van Lohuizen M, van der Lugt N,
Mizutani-Koseki Y, Kanno M, Taniguchi M, Vidal M, Alkema M, Berns A
and Koseki H: Mice doubly deficient for the polycomb group genes
Mel18 and Bmi1 reveal synergy and requirement for maintenance but
not initiation of Hox gene expression. Development. 128:1587–1597.
2001.PubMed/NCBI
|
|
33
|
Gao Z, Zhang J, Bonasio R, Strino F, Sawai
A, Parisi F, Kluger Y and Reinberg D: PCGF homologs, CBX proteins,
and RYBP define functionally distinct PRC1 family complexes. Mol
Cell. 45:344–356. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu WL, Guo XZ, Zhang LJ, Wang JY, Zhang
G, Guan S, Chen YM, Kong QL, Xu LH, Li MZ, et al: Prognostic
relevance of Bmi-1 expression and autoantibodies in esophageal
squamous cell carcinoma. BMC Cancer. 10:4672010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shi Q, Shen LY, Dong B, Fu H, Kang XZ,
Yang YB, Dai L, Yan WP, Xiong HC, Liang Z and Chen KN: The
identification of the ATR inhibitor VE-822 as a therapeutic
strategy for enhancing cisplatin chemosensitivity in esophageal
squamous cell carcinoma. Cancer Lett. 432:56–68. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Galluzzi L, Vitale I, Michels J, Brenner
C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems
biology of cisplatin resistance: Past, present and future. Cell
Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sanchez-Beato M, Sanchez E, Garcia JF,
Pérez-Rosado A, Montoya MC, Fraga M, Artiga MJ, Navarrete M,
Abraira V, Morente M, et al: Abnormal PcG protein expression in
Hodgkin's lymphoma. Relation with E2F6 and NFkappaB transcription
factors. J Pathol. 204:528–537. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Silva J, Garcia JM, Peña C, García V,
Domínguez G, Suárez D, Camacho FI, Espinosa R, Provencio M, España
P and Bonilla F: Implication of polycomb members Bmi-1, Mel-18, and
Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc
expression in primary breast carcinomas. Clin Cancer Res.
12:6929–6936. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Merkow RP, Bilimoria KY, McCarter MD, Chow
WB, Ko CY and Bentrem DJ: Use of multimodality neoadjuvant therapy
for esophageal cancer in the United States: Assessment of 987
hospitals. Ann Surg Oncol. 19:357–364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Banerjee Mustafi S, Chakraborty PK, Naz S,
Dwivedi SK, Street M, Basak R, Yang D, Ding K, Mukherjee P and
Bhattacharya R: MDR1 mediated chemoresistance: BMI1 and TIP60 in
action. Biochim Biophys Acta. 1859:983–993. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhao Q, Qian Q, Cao D, Yang J, Gui T and
Shen K: Role of BMI1 in epithelial ovarian cancer: Investigated via
the CRISPR/Cas9 system and RNA sequencing. J Ovarian Res.
11:312018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
M JR and S V: BMI1 and PTEN are key
determinants of breast cancer therapy: A plausible therapeutic
target in breast cancer. Gene. 678:302–311. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Riis ML, Luders T, Nesbakken AJ, Vollan
HS, Kristensen V and Bukholm IR: Expression of BMI-1 and Mel-18 in
breast tissue-a diagnostic marker in patients with breast cancer.
BMC Cancer. 10:6862010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tetsu O, Ishihara H, Kanno R, Kamiyasu M,
Inoue H, Tokuhisa T, Taniguchi M and Kanno M: mel-18 negatively
regulates cell cycle progression upon B cell antigen receptor
stimulation through a cascade leading to c-myc/cdc25. Immunity.
9:439–448. 1998. View Article : Google Scholar : PubMed/NCBI
|
